Recommended Starting Dose of Suboxone for Opioid Withdrawal
The recommended initial dose is 8 mg of buprenorphine on day 1, administered sublingually when objective signs of opioid withdrawal are evident, followed by 16 mg on day 2, then transitioning to Suboxone (buprenorphine/naloxone) at the same dose from day 3 onward. 1
Critical Timing Considerations
You must wait for objective withdrawal signs before administering the first dose to avoid precipitating withdrawal. The FDA label is explicit about this requirement 1. The timing depends on the type of opioid:
- Short-acting opioids (heroin, oxycodone, fentanyl): Wait at least 4 hours after last use, or preferably until early withdrawal signs appear 1
- Long-acting opioids (methadone >30 mg/day): Exercise extreme caution - withdrawal during induction is more likely and can be severe 1, 2
Induction Protocol
The FDA-approved induction strategy uses Subutex (buprenorphine alone) for days 1-2, then switches to Suboxone (buprenorphine/naloxone combination) from day 3 forward 1. This approach minimizes precipitated withdrawal risk during the vulnerable induction phase while the naloxone component provides diversion protection during maintenance.
Day-by-Day Dosing:
- Day 1: 8 mg buprenorphine (Subutex preferred)
- Day 2: 16 mg buprenorphine (Subutex)
- Day 3+: 16 mg Suboxone (maintenance phase)
The target maintenance dose is 16 mg/day of Suboxone, though doses as low as 12 mg may be effective in some patients 1. The FDA label emphasizes achieving an adequate maintenance dose "as rapidly as possible" because gradual induction over several days led to high dropout rates in clinical studies 1.
Administration Technique
Place tablets under the tongue until completely dissolved - swallowing reduces bioavailability 1. For doses requiring more than two tablets, patients can place all tablets at once or two at a time if more comfortable. Consistency in administration method is important for reliable bioavailability 1.
Common Pitfalls to Avoid
The most dangerous error is dosing too early before withdrawal onset, which can precipitate severe withdrawal due to buprenorphine's high affinity displacing full agonist opioids from receptors 1, 2. One case report describes a patient on high-dose methadone who experienced severe withdrawal, hospitalization, relapses, and suicidal ideation after rapid transition 2.
Methadone patients require special caution, particularly those on doses >30 mg/day. The risk of precipitated withdrawal is substantially higher, and some patients may fail transition entirely 1, 2. Consider alternative strategies or slower tapers for this population.
Inadequate initial dosing leads to treatment dropout - the FDA label specifically notes that gradual induction increased dropout rates, which is why the 8 mg/16 mg rapid escalation protocol is recommended 1.
Emergency Department Context
The 2020 ACEP guidelines note that ED physicians without an X-waiver can administer (but not prescribe) buprenorphine for up to 72 hours while arranging referral 3. This allows ED initiation of treatment, which can be lifesaving given that opioid withdrawal, while uncomfortable, motivates continued hazardous opioid use 3.
Dose Adjustments
After achieving the initial 16 mg target, adjust in 2-4 mg increments/decrements to suppress withdrawal and retain the patient in treatment 1. The effective range is typically 4-24 mg/day depending on individual factors 1. Clinical studies demonstrate 16 mg is effective compared to placebo, with some patients responding to 12 mg 1, 4.